AU2018311981B2 - Methods for treating active eosinophilic esophagitis - Google Patents

Methods for treating active eosinophilic esophagitis Download PDF

Info

Publication number
AU2018311981B2
AU2018311981B2 AU2018311981A AU2018311981A AU2018311981B2 AU 2018311981 B2 AU2018311981 B2 AU 2018311981B2 AU 2018311981 A AU2018311981 A AU 2018311981A AU 2018311981 A AU2018311981 A AU 2018311981A AU 2018311981 B2 AU2018311981 B2 AU 2018311981B2
Authority
AU
Australia
Prior art keywords
patient
ser
eoe
pathway inhibitor
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018311981A
Other languages
English (en)
Other versions
AU2018311981A1 (en
Inventor
Jennifer D. Hamilton
Leda MANNENT
Allen Radin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Priority claimed from PCT/US2018/045195 external-priority patent/WO2019028367A1/en
Publication of AU2018311981A1 publication Critical patent/AU2018311981A1/en
Application granted granted Critical
Publication of AU2018311981B2 publication Critical patent/AU2018311981B2/en
Priority to AU2025200955A priority Critical patent/AU2025200955A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2018311981A 2017-08-04 2018-08-03 Methods for treating active eosinophilic esophagitis Active AU2018311981B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200955A AU2025200955A1 (en) 2017-08-04 2025-02-12 Methods for treating active eosinophilic esophagitis

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762541242P 2017-08-04 2017-08-04
US62/541,242 2017-08-04
US201762561593P 2017-09-21 2017-09-21
US62/561,593 2017-09-21
EP18305252.1 2018-03-08
EP18305252 2018-03-08
PCT/US2018/045195 WO2019028367A1 (en) 2017-08-04 2018-08-03 METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200955A Division AU2025200955A1 (en) 2017-08-04 2025-02-12 Methods for treating active eosinophilic esophagitis

Publications (2)

Publication Number Publication Date
AU2018311981A1 AU2018311981A1 (en) 2020-02-20
AU2018311981B2 true AU2018311981B2 (en) 2024-11-14

Family

ID=63113646

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018311981A Active AU2018311981B2 (en) 2017-08-04 2018-08-03 Methods for treating active eosinophilic esophagitis
AU2025200955A Pending AU2025200955A1 (en) 2017-08-04 2025-02-12 Methods for treating active eosinophilic esophagitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200955A Pending AU2025200955A1 (en) 2017-08-04 2025-02-12 Methods for treating active eosinophilic esophagitis

Country Status (9)

Country Link
EP (1) EP3661551A1 (enrdf_load_stackoverflow)
JP (2) JP7417515B2 (enrdf_load_stackoverflow)
KR (2) KR102719720B1 (enrdf_load_stackoverflow)
CN (1) CN111032084A (enrdf_load_stackoverflow)
AU (2) AU2018311981B2 (enrdf_load_stackoverflow)
CA (1) CA3071528A1 (enrdf_load_stackoverflow)
IL (2) IL315556A (enrdf_load_stackoverflow)
MA (1) MA49744A (enrdf_load_stackoverflow)
MX (2) MX2020001305A (enrdf_load_stackoverflow)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3174431A1 (en) * 2020-05-22 2021-11-25 Jennifer D. Hamilton Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
AU2023259287A1 (en) * 2022-04-29 2024-12-12 Akeso Biopharma, Inc Anti-human il-4ra antibody and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI682781B (zh) * 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
KR20160068802A (ko) * 2013-10-23 2016-06-15 제넨테크, 인크. 호산구성 장애를 진단 및 치료하는 방법
KR20170123315A (ko) * 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질

Also Published As

Publication number Publication date
JP2024016237A (ja) 2024-02-06
MX2020001305A (es) 2020-03-09
CN111032084A (zh) 2020-04-17
MA49744A (fr) 2020-06-10
AU2018311981A1 (en) 2020-02-20
CA3071528A1 (en) 2019-02-07
KR20240152980A (ko) 2024-10-22
IL272245B2 (en) 2025-02-01
AU2025200955A1 (en) 2025-03-06
RU2020109331A3 (enrdf_load_stackoverflow) 2021-12-28
IL272245A (en) 2020-03-31
JP2020529434A (ja) 2020-10-08
EP3661551A1 (en) 2020-06-10
RU2020109331A (ru) 2021-09-06
IL272245B1 (en) 2024-10-01
MX2024012777A (es) 2024-11-08
KR20200035442A (ko) 2020-04-03
IL315556A (en) 2024-11-01
JP7417515B2 (ja) 2024-01-18
KR102719720B1 (ko) 2024-10-22

Similar Documents

Publication Publication Date Title
US20210363237A1 (en) Methods for treating active eosinophilic esophagitis
AU2020200497B2 (en) Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor
US20210363264A1 (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
AU2025200955A1 (en) Methods for treating active eosinophilic esophagitis
RU2776651C2 (ru) Способы лечения активного эозинофильного эзофагита
HK40029391A (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
HK1218854B (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)